Chronic Lymphocytic Leukemia News

Chronic Lymphocytic Leukemia News

Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL

Publish Date November 29, 2022

Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers

Publish Date November 15, 2022

Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.

Risk of VTE 6-Fold Higher in CLL/MBL Than in General Population

Publish Date October 25, 2022

Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.

Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors

Publish Date October 20, 2022

The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.

Immune Responses to SARS-CoV-2 mRNA Vaccines Vary in Patients With Hematologic Malignancies

Publish Date October 7, 2022

Researchers evaluated the anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies in a real-world setting.

Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL

Publish Date October 3, 2022

Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.

Triplet Falls Short in Relapsed/Refractory Chronic Lymphocytic Leukemia

Publish Date September 14, 2022

Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.

Long-Term Multicenter Study Underscores Role of 1L Cladribine in Hairy Cell Leukemia

Publish Date September 6, 2022

Researchers sought to determine the long-term clinical experience of patients with HCL treated with frontline cladribine.

New Tablet Formulation of Calquence Approved for CLL, SLL, MCL

Publish Date August 8, 2022

The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.

Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL

Publish Date July 26, 2022

Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.

FDA Warns of Increased Side Effects, Death Risk With Duvelisib

Publish Date July 1, 2022

The FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs prescribing an alternative therapy.

Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia

Publish Date June 13, 2022

Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.

Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia

Publish Date June 10, 2022

Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.

Eponyms in Oncology: Bence-Jones Protein

Publish Date May 20, 2022

This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.

Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients

Publish Date April 25, 2022

Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.

Ukoniq Taken Off the Market; Pending Applications for CLL, SLL Withdrawn

Publish Date April 18, 2022

TG Therapeutics has decided to take Ukoniq (umbralisib) off the market and withdraw pending applications for the drug.

Moderna COVID-19 Vaccine May Be More Effective in CLL Patients

Publish Date April 2, 2022

Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.

Venetoclax Plus Dose-Adjusted R-EPOCH Yields Durable Responses in Richter Syndrome

Publish Date March 31, 2022

Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.

Drugs in Phase 1 Trials Becoming More Effective, No Less Fatal

Publish Date March 22, 2022

Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.

FDA: Safety Concerns With Lymphoma Drug Ukoniq

Publish Date February 4, 2022

An initial review of data from the phase 3 UNITY trial in CLL patients showed the combination of Ukoniq and ublituximab was associated with increased risk of death compared with the control arm.